323 results
Page 3 of 17
6-K
EX-99.3
xtrv k6cbh3z0
14 Feb 22
FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease
2:07pm
6-K
EX-99.2
hwzkzpl ztsh
14 Feb 22
FDA approves Enjaymo™ (sutimlimab-jome), first treatment for use in patients with cold agglutinin disease
2:07pm
6-K
EX-99.1
8eyhn
4 Feb 22
CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe asthma with type 2 inflammation
1:29pm
6-K
EX-99.1
iil0j76kvdh4l3zf93d0
24 Jan 22
Second positive Phase 3 Dupixent® (dupilumab) trial confirms significant improvements for patients with prurigo nodularis
1:41pm
6-K
EX-99.3
pk2o5d3c
15 Dec 21
Current report (foreign)
2:50pm
6-K
EX-99.4
uq8r fl7b4
15 Dec 21
Current report (foreign)
2:50pm
6-K
EX-99.1
d0uzg 3v58
22 Nov 21
Current report (foreign)
12:42pm
6-K
EX-99.1
0rkqhwm
28 Oct 21
Q3 2021 sales grew double digit to €10.4 billion (up 10.1%) due to strong growth from Dupixent®, Vaccines and CHC
11:19am
6-K
EX-99.1
gwe zjoz52k
26 Oct 21
Current report (foreign)
5:08pm
6-K
EX-99.2
cux r4g5mwxcgvjx
26 Oct 21
Current report (foreign)
5:08pm
6-K
EX-99.3
13cufoo5mu
26 Oct 21
Current report (foreign)
5:08pm
6-K
EX-99.2
vrpr s8w35o
23 Sep 21
New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV
1:54pm
6-K
EX-99.1
10f8p7 wy
23 Sep 21
New Dupixent® (dupilumab) data in patients as young as 6 years old with moderate-to-severe atopic dermatitis to be presented at WCPD and EADV
1:54pm
6-K
EX-99.2
u8h7y9tgx8i
10 Sep 21
Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus
3:23pm
SC TO-T
EX-99
i2k6m8sn 4ktfyaqz4ga
16 Aug 21
Third party tender offer statement
8:09am
SC TO-T
EX-99
xz49194 bfw2c7utz
16 Aug 21
Third party tender offer statement
8:09am
6-K
EX-99.2
qfmsbee1s
9 Aug 21
FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease
2:54pm
6-K
EX-99.1
l2p0nb6awnybcd
9 Aug 21
FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease
2:54pm
6-K
EX-99.3
5olgnxy 7yme
2 Aug 21
Online availability of Sanofi’s half-year financial report for 2021
5:03pm
F-3ASR
EX-4.1
ug07gunu
30 Jul 21
Automatic shelf registration (foreign)
4:52pm